Ftse Mib
34.660,38
-0,50%
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
NASDAQ
17.133,13
-0,23%
Bitcoin
69.357,46
0,04%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Neurochem - Common Shares (MM) (NRMX) Neurochem - Common Shares (MM) (NRMX) Notizie

NRMX

Neurochem (NRMX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NRMX
DataOraFonteTitoloSimboloCompagnia
16/04/200817:57Edgar (US Regulatory)Neurochem Inc - Report of Foreign Issuer (6-K)NASDAQ:NRMXNeurochem - Common Shares (MM)
15/04/200814:00PR Newswire (US)At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update oNASDAQ:NRMX
11/04/200820:30PR Newswire (US)Media advisory - Neurochem's Annual and Special Meeting of Shareholders April 15, 2008NASDAQ:NRMX
11/04/200818:24PR Newswire (US)Neurochem Annual and Special Meeting of shareholdersNASDAQ:NRMX
10/04/200817:26Edgar (US Regulatory)Neurochem Inc - Amended Annual Report (foreign private issuer) (40-F/A)NASDAQ:NRMXNeurochem - Common Shares (MM)
14/03/200822:07Edgar (US Regulatory)Neurochem Inc - Annual Report (foreign private issuer) (40-F)NASDAQ:NRMXNeurochem - Common Shares (MM)
13/03/200812:00PR Newswire (US)Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosisNASDAQ:NRMX
22/02/200801:19PR Newswire (US)Neurochem announces departure of two members of management teamNASDAQ:NRMX
21/02/200822:54Edgar (US Regulatory)Neurochem Inc - Amended Report of Foreign Issuer (6-K/A)NASDAQ:NRMXNeurochem - Common Shares (MM)
21/02/200801:12PR Newswire (US)Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectivesNASDAQ:NRMX
13/02/200818:26PR Newswire (US)/C O R R E C T I O N from source -- Neurochem Inc./NASDAQ:NRMX
11/02/200816:46PR Newswire (US)Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast liveNASDAQ:NRMX
30/01/200814:00PR Newswire (US)Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical businessNASDAQ:NRMX
03/01/200819:08PR Newswire (US)Neurochem to present at JPMorgan Healthcare ConferenceNASDAQ:NRMX
14/12/200714:24PR Newswire (US)Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosisNASDAQ:NRMX
06/12/200723:09PR Newswire (US)Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 reviewNASDAQ:NRMX
30/11/200722:15PR Newswire (US)Neurochem announces departure of Dr. Philippe Calais, President, Global BusinessNASDAQ:NRMX
08/11/200713:00PR Newswire (US)Neurochem announces important initiatives to provide medical and health benefits to patientsNASDAQ:NRMXNeurochem - Common Shares (MM)
08/11/200700:55PR Newswire (US)Neurochem reports results for third quarter of fiscal 2007NASDAQ:NRMX
28/08/200719:20PR Newswire (US)Neurochem provides information on cash positionNASDAQ:NRMX
27/08/200702:02PR Newswire (US)Neurochem Announces results from Tramiprosate (ALZHEMED(TM)) North American Phase III Clinical TrialNASDAQ:NRMX
09/08/200723:05PR Newswire (US)Neurochem reports results for second quarter of fiscal 2007NASDAQ:NRMX
24/07/200713:00PR Newswire (US)Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))NASDAQ:NRMX
17/07/200721:57PR Newswire (US)Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosisNASDAQ:NRMX
26/06/200719:10PR Newswire (US)Neurochem to present at Jefferies Healthcare ConferenceNASDAQ:NRMX
22/06/200722:29PR Newswire (US)Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress updateNASDAQ:NRMX
21/06/200714:00PR Newswire (US)Neurochem receives third recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramNASDAQ:NRMX
18/06/200714:00PR Newswire (US)Neurochem Announces Mandatory and Full Conversion of All Oustanding Senior Subordinated Convertible NotesNASDAQ:NRMXNeurochem - Common Shares (MM)
11/06/200712:55PR Newswire (US)At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal InvestigNASDAQ:NRMX
07/06/200714:00PR Newswire (US)Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA(TM)) Treatment foNASDAQ:NRMX
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NRMX

La tua Cronologia

ASX
RMXR
NYSE
IPL-C.CL
LSE
0RAC
Cellnovo
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network